Toggle light / dark theme

Summary: A recently announced parabiosis trial in humans – the practice of transfusing young blood to old – may have profound implications for treating the chronic diseases of old age, including metabolic changes, frailty, Alzheimer’s, Parkinson’s, and other forms of dementia. However, some geroscientists say that variations of the procedure could cause severe side effects. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

The idea that youthful blood might rejuvenate our aging bodies has lingered in the popular imagination for centuries, fueled by recent experiments in which these transfusions revitalized aging mice.

Last week, Bill Faloon of the Life Extension Foundation (LEF) in partnership with the Young Blood Institute (YBI), announced a bold new human trial of the rejuvenating effects of the young blood / old blood swap, saying.

Read more

Five technologies in development – including senolytic drugs, rapamycin, stem cell therapy, NAD supplementation and gene therapy – could dramatically slow down aging in the next few years. This report updates the latest developments in these promising and potentially lifespan-extending treatments. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

The longevity science field has made enormous progress in recent years, and human trials of anti-aging compounds have already started, with more to begin soon. The lifespan-extension research field is gaining the attention of mainstream medicine.

The specialists who populate the field, called geroscientists, are developing several technologies that might benefit people who are alive today and aim to bring them to the clinic. These lifespan-extending technologies include stem cell therapy, rapamycin, gene therapy, senolytic drugs, and NAD supplementation.

Read more

Summary: Designer babies have recently become possible, as new techniques have gained credibility from serious scientists. Here’s how they can do it. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

On Feb 8, the AHA named “Fixing a gene mutation in human embryos” as among the “top advances in heart disease and stroke research” of the past year. They joined a chorus of voices heralding this as a research breakthrough.

The announcement brought attention to the fact that US scientists have recently demonstrated the plausibility of using gene editing to make designer babies.

Read more

Summary: In a medical first, scientists at CWRU have inhibited metastasis – the spread of cancer cells to another part of the body. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

In a first of its kind victory, researchers from the Case Western Reserve University (CWRU) School of Medicine and six other institutions have inhibited the spread of cancer cells from one part of the body to another.

To accomplish this feat, the team relied on a novel epigenetic model of how cancer metastasizes. Epigenetics is the master program which turns genes on and off. The group included researchers from the National Cancer Institute (NCI) and the Cleveland Clinic. The researchers published their results in the journal Nature Medicine.

Read more

Right in moment when Olympic games 2018 had started, founders of DAYS longevity accelerator and one of renowned longevity organizations leader have decided on running a sort of Olimpic games in life science, aiming to identify the world champions in area that really matters for everyone (life extension).

W hat is problem, why so important issue have no visible signs of progress?

If you’re sort of between 40 and older male, 40% of you will never reach the age of 74. Why multiple brilliant inventions of diagnostic and cure technologies have no financing and adoption in clinics?

Read more

What progress is being made in the field of reversing aging — the grand humanitarian project to extend healthy lifespan?

In this London Futurists online video conference, a number of healthspan extension researchers and activists from around the answered questions such as:
What do you know now, that wasn’t known, or which was less clear, back in January 2017?
What progress has encouraged you? And what disappointments have there been?
Overall, what have we learned? And what should the field do differently in the future?

We’ll discussed developments in the understanding of:
The underlying science of aging
The most effective medical interventions to slow or reverse aging
The most effective forms of advocacy, to change public opinion regarding this field
The social and economic consequences of significantly extended healthspans.

== Panellists ==